2021 ASH Annual Meeting: Focus on CLL, MCL, and WM
Preliminary data from a nonrandomized arm of the SEQUOIA trial, presented at the 2021 Annual Meeting of the American ...
Although individuals older than 80 years make up more than 20% of cases of chronic lymphocytic leukemia (CLL), this ...
Second-line therapy comprising standard rituximab plus bendamustine and bortezomib was effective and well-tolerated as a ...
A mixed-method study of Dutch patients, presented at the 63rd American Society of Hematology Annual Meeting & ...
At the 2021 American Society of Hematology (ASH) Annual Meeting, researchers presented long-term follow-up data from a ...
Patients with mantle cell lymphoma (MCL), Waldenström macroglobulinemia (WM), marginal zone lymphoma (MZL), and chronic ...
At the 2021 American Society of Hematology Annual Meeting and Exposition, Fabio Efficace, PhD, and a team of researchers ...
According to updated data from the phase I/II BRUIN study, presented at the 2021 American Society of Hematology Annual ...
Following its FDA approval in 2020 based on results from the ZUMA-2 trial, brexucabtagene autoleucel (brexu-cel) has ...
According to a poster presented at the 2021 ASH Annual Meeting by Andrew R. Branagan, MD, PhD, and colleagues, patients ...
Second-generation oral Bruton tyrosine kinase (BTK) inhibitor tirabrutinib demonstrated sustained efficacy in ...
Time-limited treatment with bendamustine, rituximab, and venetoclax was associated with high rates of undetectable ...
Frontline treatment with ibrutinib in combination with venetoclax induced deep responses in patients with previously ...
For patients with previously untreated Richter’s transformation (RT), treatment with venetoclax, obinutuzumab, and ...
Acalabrutinib monotherapy demonstrated a sustained benefit for treatment of relapsed/refractory chronic lymphocytic ...
An analysis aimed to discern baseline demographics, symptoms, and survival outcomes of Waldenström macroglobulinaemia ...
A phase II study presented at the 2021 Annual Meeting & Exposition of the American Society of Hematology, reported ...
In the phase II CITADEL-205 study, roughly two-thirds of patients with relapsed/refractory and Bruton tyrosine kinase ...
A recent study of KTE-X19 (also known as brexucabtagene autoleucel) supports the use of chimeric antigen receptor (CAR) ...
A study aimed to assess the efficacy and safety of three venetoclax (V) plus CD20 antibody-based regimens in comparison ...
An analysis of real-world data regarding the treatment of patients with chronic lymphocytic leukemia revealed that ...
Patients with treatment-naïve Waldenström macroglobulinemia (WM) who receive frontline immunochemotherapy have ...
A study that reviewed response and survival outcomes in Waldenström macroglobulinemia (WM) patients who underwent ...
Treatment with a combination of the BTK inhibitor zanubrutinib, the CD20 antibody obinutuzumab, and the BCL2 inhibitor ...
Five-year follow-up data from the phase III MCL Younger trial found a sustained benefit associated with high-dose ...
Advertisement
Advertisement
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.